Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWX203 in Healthy Chinese Subjects
NCT07799025Phase 1Active, not recruiting
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MWX203 in hyperlipidemia (6 cohorts), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoint: Incidence of adverse events. Started Jul 2025; status: active, not recruiting.
02
Drugs
MWX203
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07799025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07799025.